GPCR
BUY
Conviction: 3/5
$2B
Structure Therapeutics
Current: $42
Investment Thesis
Leading oral small molecule GLP-1 play. Aleniglipron (GSBR-1290) showed 11-15% weight loss in Phase 2b ACCESS study, competitive with injectable GLP-1s. Phase 3 expected mid-2026. Differentiated oral approach could capture significant market share in the $100B+ obesity market. Pipeline includes amylin agonist (ACCG-2671) for next-gen obesity treatment.
Bull Case
Aleniglipron Phase 3 success would validate oral GLP-1 approach, potentially capturing 10-15% of obesity market. Oral convenience drives superior compliance vs injectables. ACCG-2671 provides next-gen obesity optionality.
Bear Case
Phase 3 execution risk. GI tolerability may limit dose escalation. Competition from Lilly, Novo, and other oral GLP-1 entrants. Manufacturing scale-up challenges.
Drug Portfolio (5)
| Drug | Stage | Role | Ownership | Area | Modality |
|---|
| ACCG-2671 | PHASE1 | ORIGINATOR | 100% | CVRM | Small molecule |
| ACCG-3535 | PRECLINICAL | ORIGINATOR | 100% | CVRM | Small molecule |
| ANPA-0073 | PHASE1 | ORIGINATOR | 100% | CVRM | Small molecule |
| LTSE-2578 | PHASE1 | ORIGINATOR | 100% | R&I | Small molecule |
Financials (USD)
| Period | Revenue ($M) | Gross Margin | R&D | SG&A | Op Income | Op Margin | Net Income | EPS |
|---|
| 2023A | $5 | 100.0% | $150 | $45 | $-190 | -3800.0% | $-175 | $-3.25 |
| 2024A | $8 | 100.0% | $200 | $55 | $-247 | -3087.5% | $-222 | $-3.85 |
| 2025A | $10 | 100.0% | $220 | $60 | $-270 | -2700.0% | $-250 | $-4.00 |
| 2026E | $15 | 100.0% | $230 | $65 | $-280 | -1866.7% | $-260 | $-4.00 |
| 2027E | $50 | 100.0% | $200 | $70 | $-220 | -440.0% | $-200 | $-2.85 |
| 2028E | $100 | 90.0% | $180 | $80 | $-170 | -170.0% | $-155 | $-2.15 |
Recent Quarters
| Quarter | Revenue ($M) | Gross Margin | Op Margin | EPS |
|---|
| Q4 2025 | $3 | 100.0% | -2366.7% | $-1.05 |
| Q4 2024 | $2 | 100.0% | -3450.0% | $-1.02 |
| Q3 2025 | $2 | 100.0% | -3450.0% | $-1.02 |
| Q3 2024 | $2 | 100.0% | -3200.0% | $-0.99 |
| Q2 2026E | $4 | 100.0% | -2333.3% | $-1.00 |
| Q2 2025 | $3 | 100.0% | -2200.0% | $-0.98 |
Catalysts (6)
Aleniglipron - Obesity - FDA Type B EoP2 Meeting
REGULATORY
SM
ir.structuretx.com ACCESS PR Dec 8, 2025
H1 2026
Aleniglipron - Obesity - Ph3 - Start
CLINICAL
SM
ir.structuretx.com ACCESS PR Dec 8, 2025
Mid-2026
Aleniglipron - ACCESS Full Data - Medical Meeting
CLINICAL
ir.structuretx.com, typical development timeline
2026
ANPA-0073 - Muscle-Sparing Weight Loss - Ph2 Decision
CLINICAL
ir.structuretx.com Q2 2025 Earnings
2026
ACCG-2671 - Obesity (Amylin) - Ph1 - Data
CLINICAL
SM
ir.structuretx.com, typical Ph1 timeline
H2 2026
LTSE-2578 - IPF - Ph2 Potential Start
CLINICAL
ir.structuretx.com quarterly updates
2026
Open Debates (2)
Underappreciated Growth Driver: GPCR Platform Beyond Aleniglipron
Bull
Structure's platform designs oral small molecules for GPCRs — a target class historically considered "undruggable" for oral. ACCG-2671 (next-gen GLP-1), ANPA-0073 (GIPR agonist), and LTSE-2578 (inflammation) represent platform optionality. If aleniglipron Phase 3 succeeds, it validates the platform and de-risks follow-on programs. The platform value could double the company's worth beyond aleniglipron alone.
Bear
All pre-revenue, pre-Phase 3. Single clinical readout (aleniglipron Ph3) determines survival. Platform story means nothing if the lead asset fails.
Conviction: 5/5
Underappreciated Risk: Orforglipron (LLY) First-Mover Advantage in Oral GLP-1
Bull
The obesity market is $150B+ — room for multiple oral GLP-1s. Aleniglipron may have a differentiated efficacy/tolerability profile. Phase 3 data will differentiate.
Bear
LLY orforglipron has PDUFA Mar 2026 — potential approval while aleniglipron is still in Phase 3. If orforglipron establishes the oral GLP-1 category, it captures physician mindshare, formulary positioning, and patient awareness first. Second-to-market in a category defined by the first-mover faces massive commercial headwinds. LLY's commercial infrastructure dwarfs Structure's. Even with strong Phase 3 data, GPCR would need a partner to commercialize — further diluting economics.
Conviction: 5/5
Data from Supabase · Updated 2026-03-24